Cancer ResearchHidden Immune Backup Cell Could Make mRNA Cancer Vaccines Far More Powerful
Researchers at Washington University School of Medicine discovered that mRNA cancer vaccines work through an unexpected immune mechanism. Scientists long believed a dendritic cell subtype called cDC1 was essential for triggering anti-tumor immunity. But in mouse experiments, when cDC1 cells were removed, a closely related cell type called cDC2 stepped in and still mounted a strong tumor-fighting response. This built-in immune backup system suggests the vaccines are more robust than previously thought. Published in Nature, the findings could help researchers design more targeted and effective cancer vaccines, potentially improving outcomes for patients with melanoma, lung cancer, bladder cancer, and other tumors currently being targeted in mRNA vaccine trials.
